Literature DB >> 17988082

Agonists of Toll-like receptor 9 containing synthetic dinucleotide motifs.

Dong Yu1, Mallikarjuna R Putta, Lakshmi Bhagat, Yukui Li, Fugang Zhu, Daqing Wang, Jimmy X Tang, Ekambar R Kandimalla, Sudhir Agrawal.   

Abstract

Oligodeoxynucleotides (ODNs) containing unmethylated CpG motifs activate Toll-like receptor 9 (TLR9). Our previous studies have shown that ODNs containing two 5'-ends are more immunostimulatory than those with one 5'-end. In the present study, to understand the role of functional groups in TLR9 recognition and subsequent immune response, we substituted C or G of a CpG dinucleotide with 5-OH-dC, 5-propyne-dC, furano-dT, 1-(2'-deoxy-beta- d-ribofuranosyl)-2-oxo-7-deaza-8-methyl-purine, dF, 4-thio-dU, N(3)-Me-dC, N (4)-Et-dC, Psi-iso-dC, and arabinoC or 7-deaza-dG, 7-deaza-8-aza-dG, 9-deaza-dG, N(1)-Me-dG, N(2)-Me-dG, 6-Thio-dG, dI, 8-OMe-dG, 8-O-allyl-dG, and arabinoG in ODN containing two 5'-ends. Agonists of TLR9 containing cytosine or guanine modification showed activity in HEK293 cells expressing TLR9, mouse spleen, and human cell-based assays and in vivo in mice. The results presented here provide insight into which specific chemical modifications at C or G of the CpG motif are recognized by TLR9 and the ability to modulate immune responses substituting natural C or G in immune modulatory oligonucleotides.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17988082     DOI: 10.1021/jm070881l

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver.

Authors:  Ashley T Martino; Masataka Suzuki; David M Markusic; Irene Zolotukhin; Renee C Ryals; Babak Moghimi; Hildegund C J Ertl; Daniel A Muruve; Brendan Lee; Roland W Herzog
Journal:  Blood       Date:  2011-04-07       Impact factor: 22.113

2.  Immune-Stimulatory Dinucleotide at the 5'-End of Oligodeoxynucleotides Is Critical for TLR9-Mediated Immune Responses.

Authors:  Mallikarjuna R Putta; Lakshmi Bhagat; Daqing Wang; Fu-Gang Zhu; Ekambar R Kandimalla; Sudhir Agrawal
Journal:  ACS Med Chem Lett       Date:  2013-01-29       Impact factor: 4.345

3.  Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma.

Authors:  Cara Haymaker; Daniel H Johnson; Ravi Murthy; Salah-Eddine Bentebibel; Marc I Uemura; Courtney W Hudgens; Houssein Safa; Marihella James; Robert H I Andtbacka; Douglas B Johnson; Montaser Shaheen; Michael A Davies; Shah Rahimian; Srinivas K Chunduru; Denái R Milton; Michael T Tetzlaff; Willem W Overwijk; Patrick Hwu; Nashat Gabrail; Sudhir Agrawal; Gary Doolittle; Igor Puzanov; Joseph Markowitz; Chantale Bernatchez; Adi Diab
Journal:  Cancer Discov       Date:  2021-03-11       Impact factor: 39.397

4.  TLR9 agonist protects mice from radiation-induced gastrointestinal syndrome.

Authors:  Subhrajit Saha; Payel Bhanja; Laibin Liu; Alan A Alfieri; Dong Yu; Ekambar R Kandimalla; Sudhir Agrawal; Chandan Guha
Journal:  PLoS One       Date:  2012-01-04       Impact factor: 3.240

Review 5.  The Maternal Diet, Gut Bacteria, and Bacterial Metabolites during Pregnancy Influence Offspring Asthma.

Authors:  Lawrence E K Gray; Martin O'Hely; Sarath Ranganathan; Peter David Sly; Peter Vuillermin
Journal:  Front Immunol       Date:  2017-03-31       Impact factor: 7.561

Review 6.  The Evolution of Antisense Oligonucleotide Chemistry-A Personal Journey.

Authors:  Sudhir Agrawal
Journal:  Biomedicines       Date:  2021-05-03

7.  Design, synthesis and biological evaluation of novel antagonist compounds of Toll-like receptors 7, 8 and 9.

Authors:  Ekambar R Kandimalla; Lakshmi Bhagat; Daqing Wang; Dong Yu; Tim Sullivan; Nicola La Monica; Sudhir Agrawal
Journal:  Nucleic Acids Res       Date:  2013-02-08       Impact factor: 16.971

8.  Duodenal microbiota composition and mucosal homeostasis in pediatric celiac disease.

Authors:  Jing Cheng; Marko Kalliomäki; Hans G H J Heilig; Airi Palva; Hannu Lähteenoja; Willem M de Vos; Jarkko Salojärvi; Reetta Satokari
Journal:  BMC Gastroenterol       Date:  2013-07-11       Impact factor: 3.067

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.